West Paces Advisors’s ResMed RMD Stock Holding History

West Paces Advisors’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2	Closed	-$448	–	487
2025 Q1	$448	Hold	2	–	–	﹤0.01%	536
2024 Q4	$457	Hold	2	–	–	﹤0.01%	526
2024 Q3	$488	Hold	2	–	–	﹤0.01%	516
2024 Q2	$383	Hold	2	–	–	﹤0.01%	539
2024 Q1	$396	Sell	2 -4	-67%	-$733	﹤0.01%	555
2023 Q4	$1.03K	Buy	+6	New	+$922	﹤0.01%	505
2023 Q3	–	Sell	-4	Closed	-$874	–	554
2023 Q2	$874	Hold	4	–	–	﹤0.01%	498
2023 Q1	$876	Buy	4 +1	+33%	+$217	﹤0.01%	517
2022 Q4	$624	Sell	3 -4	-57%	-$879	﹤0.01%	496
2022 Q3	$1.53K	Hold	7	–	–	﹤0.01%	446
2022 Q2	$1.47K	Buy	7 +3	+75%	+$639	﹤0.01%	502
2022 Q1	$970	Buy	+4	New	+$968	﹤0.01%	531
2021 Q3	–	Sell	-108	Closed	-$26.6K	–	628
2021 Q2	$26.6K	Sell	108 -112	-51%	-$23.5K	0.01%	260
2021 Q1	$42.7K	Buy	+220	New	+$44.1K	0.02%	205

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

West Paces Advisors's RMD Position: Q2 2025 in Review

West Paces Advisors sold out of ResMed (RMD) in Q2 2025, closing a stake of 2 shares — an estimated $448 sold.

West Paces Advisors first reported a position in RMD in Q1 2021 and held it in 14 quarters. The position peaked at $42.7K in Q1 2021. 919 funds tracked by Wall St. Rank hold RMD as of Q2 2025.

West Paces Advisors reported no remaining ResMed position as of Q2 2025 after selling out during the quarter.
West Paces Advisors sold 2 ResMed shares in Q2 2025, an estimated $448.
West Paces Advisors first reported a position in ResMed in Q1 2021 and held it in 14 quarters.
West Paces Advisors's ResMed position peaked at $42.7K in Q1 2021.
919 funds tracked by Wall St. Rank held ResMed as of Q2 2025.

Based on West Paces Advisors's 13F filing for Q2 2025, filed 23 Jul 2025.